Browsing by Author "Mentes, S."

Now showing 1 - 3 of 3

The Effects of Radiotherapy on Arterial Diameters in Patients With High-Grade Glial Tumors Who Have Undergone Adjuvant Radiotherapy
(Wolters Kluwer Medknow Publications, 2023) Karaca, F.; Mentes, S.; Boga, Z.; Akkaya, H.; Keskin, S.; Gulek, B.
Background and Aims:Our purpose was to evaluate the M2 branch of the middle cerebral artery (MCA) in high-grade glial tumor patients who undergo adjuvant radiotherapy (RT). For this purpose, the diameter of the M2 branch was measured and evaluated by means of contrast-enhanced magnetic resonance imaging (CE-MRI) before and after RT. Post-radiotherapeutical measurements were made 1, 3, 5, and 7 months after the procedure; and vascular diameter alterations were evaluated. Materials and Methods:CE-MRI examinations were performed on the 32 patients enrolled in the study, who had undergone radiotherapy of the temporoparietal region. MRI examinations were performed prior to RT (RT0) and 1 (RT1), 3 (RT2), 5 (RT3), and 7 (RT4) months after RT. The M2 branch of the MCA was evaluated on MRI images, and the vessel diameter was measured in millimeters (mm), and then comparisons were made. Results:Statistically significant results were obtained during RT0-RT1, RT0-RT2, RT0-RT3, RT0-RT4, RT1-RT2, RT2-RT4, and RT3-RT4, and comparisons of the diameters of the M2 branch of the right MCA were performed (P < 0.05). When the same measurements and comparisons were made for the M2 branch of the left MCA, statistically significant results were found for the RT1-RT2, RT1-RT3, and RT1-RT4 comparisons (P < 0.05). Conclusion:Our study showed that the MCA M2 branch diminished in size following RT. This was demonstrated by means of CE-MRI controls performed up to 7 months after the completion of the RT procedures.
Evaluating Interleukin-16 Expression in Patients With Grade-3 and Grade-4 Glial Cell Tumors and Healthy Individuals
(Wolters Kluwer Medknow Publications, 2023) Karaca, F.; Keskin, S.; Mentes, S.; Boga, Z.; Cavus, G.; Koksal, F.
Background: This study evaluated the change in IL-16 levels in patients with high-grade glial tumors undergoing radiotherapy (RT) and healthy individuals (control group).Materials and Methods: Serum IL-16 levels of 35 high-grade glioma patients receiving radiotherapy (RT) and 30 healthy individuals were compared. We compared the IL-16 levels before (RT0) and after the (RT1) and IL-16 levels were measured and the relationship of this change with other characteristics such as age, gender, weight, height, and blood test results. Results: The RT0-IL-16 level was approximately 15 pg/ml higher than the RT1 measurement in the patient group. The mean RT0-IL-16 levels in the patient group were approximately 10 pg/ml higher than the mean IL-16 levels in the control group. Likewise, at the RT1 time-point, the mean IL-16 levels for the patient group were approximately 5 pg/ml lower than the mean IL-16 for the control group. The mean RT0-RT1-IL-16 value tended to be higher in female patients than in male patients. Conclusion: The application of RT reduces the overall IL-16 levels, suggesting the efficacy of RT, as well as the role of IL-16 in tumorigenesis.
Evaluation of Il-17a Expressions in High-Grade Glial Tumors Receiving Radiotherapy
(Wolters Kluwer Medknow Publications, 2022) Karaca, F.; Keskin, S.; Mentes, S.; Okten, A., I; Cavus, G.; Arslan, A.; Koksal, F.
Aim: In this study, we aimed to investigate the interleukin-17A (IL-17A) levels in patients with high-grade glial tumors before receiving radiotherapy, immediately after radiotherapy, and 3 months after radiotherapy. Patients and Methods: A total of 33 patients who applied to Adana City Training and Research Hospital, Department of Radiation Oncology between December 2016 and May 2018 was included in this study. A total of three blood samples was taken from each patient to assess IL-17A levels before and after radiotherapy and 3 months after the completion of radiotherapy. Results: The differences in IL-17A levels between genders were not statistically significant. IL-17A levels progressively decreased after the radiotherapy and 3 months after the radiotherapy as compared to the levels before radiotherapy. However, this was not statistically significant. IL-17A levels in the non-surviving patients were high before and after radiotherapy as compared to the surviving ones, but this was also not statistically significant. Conclusion: As compared to the period before radiotherapy, IL-17A levels tend to decrease in the period of acute and chronic phases of radiotherapy in all patient groups.